OrbiMed’s Roivant Sciences ROIV Stock Holding History

OrbiMed’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,190,907	Closed	-$47.5M	–	127
2025 Q4	$47.5M	Sell	2,190,907 -523,891	-19%	-$10.3M	0.97%	30
2025 Q3	$41.1M	Sell	2,714,798 -64,629	-2%	-$800K	0.97%	35
2025 Q2	$31.3M	Buy	+2,779,427	New	+$30.1M	0.78%	33

Other funds holding ROIV

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

OrbiMed's ROIV Position: Q1 2026 in Review

OrbiMed sold out of Roivant Sciences (ROIV) in Q1 2026, closing a stake of 2,190,907 shares — an estimated $47.5M sold.

OrbiMed first reported a position in ROIV in Q2 2025 and held it in 3 quarters. The position peaked at $47.5M in Q4 2025. 444 funds tracked by Wall St. Rank hold ROIV as of Q1 2026.

OrbiMed reported no remaining Roivant Sciences position as of Q1 2026 after selling out during the quarter.
OrbiMed sold 2,190,907 Roivant Sciences shares in Q1 2026, an estimated $47.5M.
OrbiMed first reported a position in Roivant Sciences in Q2 2025 and held it in 3 quarters.
OrbiMed's Roivant Sciences position peaked at $47.5M in Q4 2025.
444 funds tracked by Wall St. Rank held Roivant Sciences as of Q1 2026.

Based on OrbiMed's 13F filing for Q1 2026, filed 15 May 2026.